RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
JOURNAL OF THORACIC ONCOLOGY(2021)
关键词
PD-1, immunotherapy, NSCLC
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF THORACIC ONCOLOGY(2021)